# Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

> **NCT06543381** · PHASE1 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 15 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Olutasidenib

## Key facts

- **NCT ID:** NCT06543381
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-17
- **Primary completion:** 2027-02-05
- **Final completion:** 2027-02-05
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06543381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06543381, "Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06543381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*